> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the biopharma industry. Story [1]
> Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. Report [2]
> Celera has granted Merck a two-year license covering access to up to 10 cancer therapies. Release [3]
> Bausch & Lomb has forged a deal to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases. Release [4]
> Rep. Henry Waxman and 26 of his Congressional counterparts are wading into the compulsory licensing fray. Report [5]
> Roche is appealing to a higher power on Mircera. Report [6]
> What does Exubera's possible cancer link teach us about drug safety? Report [7]
And Finally... Fuzzy-headed today? Then pop a pill. Professionals of all kinds are doing it these days, according to a survey taken by Nature. Report [8]
Links:
[1] http://www.bizjournals.com/sacramento/stories/2008/04/07/daily47.html
[2] http://www.fiercebioresearcher.com/vaccines/story/crucell-reports-early-stage-success-with-tb-vaccine/2008-04-10
[3] http://www.fiercebiotech.com/press-releases/celera-genomics-group-applera-corp-business-grants-license-merck-cancer-targets
[4] http://www.fiercebiotech.com/press-releases/bausch-lomb-and-galapagos-nv-sign-agreement-collaborate-ophthalmic-disease-research
[5] http://www.fiercepharma.com/story/dems-back-compulsory-licensing/2008-04-10
[6] http://www.fiercepharma.com/story/roche-appeals-mircera-injunction/2008-04-10
[7] http://www.fiercepharma.com/story/what-exubera-says-about-safety/2008-04-10
[8] http://www.fiercepharma.com/story/pros-use-pills-to-boost-brainpower/2008-04-10